News
FRANKLIN LAKES, N.J., July 23, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announces the first pharma-sponsored combination ...
Successful feasibility study underscores compatibility of STAR-LLD using On-body Injector (OBI) technology and Starton’s proprietary low-dose formulation of lenalidomide (LLD) Based on the positive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback